TCT 2009 schedule: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Apalmer (talk | contribs)
nocaptcha
14,582 edits
Apalmer (talk | contribs)
nocaptcha
14,582 edits
No edit summary
Line 1: Line 1:
Here is the page we will use to coordinate the TV events at TCT 2009.
Here is the page we will use to coordinate the TV events at TCT 2009. The filming will take place in Room East 264 at the Moscone Convention Center.


----
----
Line 5: Line 5:


==Click on Date for Detailed Schedule==
==Click on Date for Detailed Schedule==
[[{{PAGENAME}}#Monday September 21, 2009|Monday September 21, 2009]]


[[{{PAGENAME}}#Tuesday September 22, 2009|Tuesday September 22, 2009]]
[[{{PAGENAME}}#Tuesday September 22, 2009|Tuesday September 22, 2009]]
Line 18: Line 16:
----
----


== Monday September 21, 2009==
===1:05 PM===
''1:05 PM - 1:15 PM''
*'''Event:''' The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
*'''Room:''' 104
===1:51 PM===
''1:51 PM - 2:03 PM''
*'''Event:''' The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
*'''Room:''' 104
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''


== Tuesday September 22, 2009==
== Tuesday September 22, 2009==
===10:00 AM===
''10:00 AM - 12:00 PM''
*'''Event:''' Oral Abstracts- AMI
*'''Room:''' 125


===12:30 PM===
===12:30 PM===
''12:30 PM - 1:00 PM''
''12:30 PM - 1:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Pieter C. Smits
*'''Interviewee:''' Pieter C. Smits
*'''Trial: ''' COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents   
*'''Trial: ''' COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents   
*'''Phone number:'''
*'''Phone number:'''


===1:00 PM===
===1:00 PM===
''1:00 PM - 1:30 PM''
''1:00 PM - 1:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Shamir Mehta
*'''Interviewee:''' Shamir Mehta
*'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS     
*'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS     
*'''Phone number:'''
*'''Phone number:'''


===2:00 PM===
===2:00 PM===
''2:00 PM - 2:30 PM''
''2:00 PM - 2:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' John Spertus
*'''Interviewee:''' John Spertus
*'''Trial: ''' NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent  
*'''Trial: ''' NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent  
*'''Phone number:'''
*'''Phone number:'''


===2:30 PM===
===2:30 PM===
''2:30 PM - 3:00 PM''
''2:30 PM - 3:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Eberhard Grube
*'''Interviewee:''' Eberhard Grube
*'''Trial: ''' BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent  
*'''Trial: ''' BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent  
*'''Phone number:'''
*'''Phone number:'''


===3:00 PM===
===3:00 PM===
''3:00 PM - 3:30 PM''
''3:00 PM - 3:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' David Allie
*'''Interviewee:''' David Allie
*'''Trial: ''' CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
*'''Trial: ''' CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
*'''Phone number:'''
*'''Phone number:'''


===3:30 PM===
===3:30 PM===
''3:30 PM - 4:00 PM''
''3:30 PM - 4:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Douglas Losordo
*'''Interviewee:''' Douglas Losordo
*'''Trial: ''' ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina  
*'''Trial: ''' ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina  
*'''Phone number:'''
*'''Phone number:'''


===4:00 PM===
===4:00 PM===
''4:00 PM - 4:30 PM''
''4:00 PM - 4:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Gary Ansel
*'''Interviewee:''' Gary Ansel
*'''Trial: ''' ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting  
*'''Trial: ''' ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting  
*'''Phone number:'''
*'''Phone number:'''


===4:30 PM===
===4:30 PM===
''4:30 PM - 5:00 PM''
''4:30 PM - 5:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Ran Kornowski
*'''Interviewee:''' Ran Kornowski
*'''Trial: '''   
*'''Trial: '''   
*'''Phone number:'''
*'''Phone number:'''




Line 120: Line 74:
===8:30 AM===
===8:30 AM===
''8:30 AM - 9:00 AM''
''8:30 AM - 9:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' William Fearon
*'''Interviewee:''' William Fearon
*'''Confirmed:''' Yes
*'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease     
*'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease     
*'''Phone number:'''
*'''Phone number:'''
Line 129: Line 80:
===9:00 AM===
===9:00 AM===
''9:00 AM - 9:30 AM''
''9:00 AM - 9:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Lorenz Raber
*'''Interviewee:''' Lorenz Raber
*'''Confirmed:''' Yes
*'''Trial: ''' SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents                             
*'''Trial: ''' SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents                             
*'''Phone number:'''
*'''Phone number:'''
Line 138: Line 86:
===9:30 AM===
===9:30 AM===
''9:30 AM - 10:00 AM''
''9:30 AM - 10:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Volker Klauss
*'''Interviewee:''' Volker Klauss
*'''Confirmed:''' Yes
*'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
*'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
*'''Phone number:'''
*'''Phone number:'''
Line 147: Line 92:
===10:00 AM===
===10:00 AM===
''10:00 AM - 10:30 AM''
''10:00 AM - 10:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Deepak Bhatt
*'''Interviewee:''' Deepak Bhatt
*'''Confirmed:''' Yes
*'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel  
*'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel  
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
Line 157: Line 99:
===10:30 AM===
===10:30 AM===
''10:30 AM - 11:00 AM''
''10:30 AM - 11:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' David Cohen
*'''Interviewee:''' David Cohen
*'''Confirmed:''' Yes
*'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI   
*'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI   
*'''Phone number:'''
*'''Phone number:'''
Line 166: Line 105:
===11:00 AM===
===11:00 AM===
''11:00 AM - 11:30 AM''
''11:00 AM - 11:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Chris Cannon
*'''Interviewee:''' Chris Cannon
*'''Confirmed:''' Yes
*'''Trial: ''' PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
*'''Trial: ''' PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
*'''Phone number:'''  
*'''Phone number:'''  
Line 175: Line 111:
===12:00 PM===
===12:00 PM===
''12:00 PM - 12:30 PM''
''12:00 PM - 12:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Robert Byrne
*'''Interviewee:''' Robert Byrne
*'''Confirmed:''' Yes
*'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents  
*'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents  
*'''Phone number:'''     
*'''Phone number:'''     


===12:45 PM===
''12:45 PM - 12:50 PM''
*'''Event:''' Open Issues I: Adjunct Pharmacology. Schedule
*'''Room:''' 130
===1:35 PM===
''1:35 PM - 1:45 PM''
*'''Event:''' Open Issues I: Adjunct Pharmacology. Schedule
*'''Room:''' 130
===4:00 PM===
''4:00 PM - 4:45 PM''
*'''Event:''' Main Arena I. Plenary Session #7 Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy
*'''Room:''' Esplanade Ballroom


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''


== Thursday September 24, 2009==
== Thursday September 24, 2009==
===8:46 AM===
''8:46 AM - 11:11 AM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 2: Current Choices in Antithrombin Therapy for ACS and PCI
*'''Room:''' 135
===11:45 PM===
''11:45 AM - 11:57 AM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
*'''Room:''' 135
===12:09 PM===
''12:09 PM - 12:24 PM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
*'''Room:''' 135


===12:45 PM===
===12:45 PM===
''12:45 PM - 1:15 PM''
''12:45 PM - 1:15 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Cheol Whan Lee
*'''Interviewee:''' Cheol Whan Lee
*'''Trial: ''' 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel   
*'''Trial: ''' 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel   
Line 226: Line 128:
===1:15 PM===
===1:15 PM===
''1:15 PM - 1:45 PM''
''1:15 PM - 1:45 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Flavio Ribichini   
*'''Interviewee:''' Flavio Ribichini   
*'''Trial: ''' CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation     
*'''Trial: ''' CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation     
Line 234: Line 134:
===1:45 PM===
===1:45 PM===
''1:45 PM - 2:15 PM''
''1:45 PM - 2:15 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Josef Veselka  
*'''Interviewee:''' Josef Veselka  
*'''Trial: ''' STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina     
*'''Trial: ''' STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina     
Line 242: Line 140:
===2:15 PM===
===2:15 PM===
''2:15 PM - 2:45 PM''
''2:15 PM - 2:45 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Patrick Ohlmann
*'''Interviewee:''' Patrick Ohlmann
*'''Trial: ''' MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI     
*'''Trial: ''' MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI     
Line 250: Line 146:
===2:45 PM===
===2:45 PM===
''2:45 PM - 3:15 PM''
''2:45 PM - 3:15 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Junbo Ge
*'''Interviewee:''' Junbo Ge
*'''Trial: ''' NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI     
*'''Trial: ''' NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI     
Line 258: Line 152:
===3:15 PM===
===3:15 PM===
''3:15 PM - 3:45 PM''
''3:15 PM - 3:45 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Giulio Guagliumi
*'''Interviewee:''' Giulio Guagliumi
*'''Trial: ''' OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT     
*'''Trial: ''' OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT     
Line 266: Line 158:
===3:45 PM===
===3:45 PM===
''3:45 PM - 4:15 PM''
''3:45 PM - 4:15 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Josep Rodes-Cabau
*'''Interviewee:''' Josep Rodes-Cabau
*'''Trial: ''' The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis     
*'''Trial: ''' The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis     
Line 274: Line 164:
===4:15 PM===
===4:15 PM===
''4:15 PM - 4:45 PM''
''4:15 PM - 4:45 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Dirk Walter
*'''Interviewee:''' Dirk Walter
*'''Trial: ''' PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease     
*'''Trial: ''' PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease     
*'''Phone number:'''
*'''Phone number:'''


===5:02 PM===
''5:02 PM - 5:14 PM''
*'''Event:''' Balancing Safety and Efficacy of Antithrombotic Therapies for PCI and ACS. Antiplatelet Agents, Bleeding, and Ischemia
*'''Room:''' 135


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
Line 291: Line 175:
===10:30 AM===
===10:30 AM===
''10:30 AM - 11:00 AM''
''10:30 AM - 11:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Simon Redwood
*'''Interviewee:''' Simon Redwood
*'''Confirmed:''' Yes
*'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
*'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
*'''Phone number:'''
*'''Phone number:'''
Line 300: Line 181:
===11:00 AM===
===11:00 AM===
''11:00 AM - 11:30 AM''
''11:00 AM - 11:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Arnold Seto
*'''Interviewee:''' Arnold Seto
*'''Confirmed:''' Yes
*'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
*'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
*'''Phone number:'''
*'''Phone number:'''
Line 309: Line 187:
===12:30 PM===
===12:30 PM===
''12:30 PM - 1:00 PM''
''12:30 PM - 1:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Rolf Michels
*'''Interviewee:''' Rolf Michels
*'''Confirmed:''' Yes
*'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
*'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
*'''Phone number:'''
*'''Phone number:'''
Line 318: Line 193:
===1:00 PM===
===1:00 PM===
''1:00 PM - 1:30 PM''
''1:00 PM - 1:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Gregg Stone
*'''Interviewee:''' Gregg Stone
*'''Confirmed:''' Yes
*'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
*'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI
Line 328: Line 200:
===1:30 PM===
===1:30 PM===
''1:30 PM - 2:00 PM''
''1:30 PM - 2:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Henry Krum
*'''Interviewee:''' Henry Krum
*'''Confirmed:''' Yes
*'''Trial: ''' SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
*'''Trial: ''' SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
*'''Phone number:'''
*'''Phone number:'''


===2:24 PM===
''2:24 PM - 2:36 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
GPIIb/IIIa Inhibitors in ACS: EARLY ACS
*'''Room:''' EBM and Guidelines Theater, Hall D
===2:36 PM===
''2:36 PM - 3:12 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
*'''Room:''' EBM and Guidelines Theater, Hall D
===3:00 PM===
''3:00 PM - 3:12 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
*'''Room:''' EBM and Guidelines Theater, Hall D
===3:24 PM===
''3:24 PM - 3:36 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
*'''Room:''' EBM and Guidelines Theater, Hall D
===3:36 PM===
''3:36 PM - 3:48 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
*'''Room:''' EBM and Guidelines Theater, Hall D


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''

Revision as of 16:46, 27 August 2009

Here is the page we will use to coordinate the TV events at TCT 2009. The filming will take place in Room East 264 at the Moscone Convention Center.


Click on Date for Detailed Schedule

Tuesday September 22, 2009

Wednesday September 23, 2009

Thursday September 24, 2009

Friday September 25, 2009


Tuesday September 22, 2009

12:30 PM

12:30 PM - 1:00 PM

  • Interviewee: Pieter C. Smits
  • Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
  • Phone number:

1:00 PM

1:00 PM - 1:30 PM

  • Interviewee: Shamir Mehta
  • Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  • Phone number:

2:00 PM

2:00 PM - 2:30 PM

  • Interviewee: John Spertus
  • Trial: NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
  • Phone number:

2:30 PM

2:30 PM - 3:00 PM

  • Interviewee: Eberhard Grube
  • Trial: BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
  • Phone number:

3:00 PM

3:00 PM - 3:30 PM

  • Interviewee: David Allie
  • Trial: CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
  • Phone number:

3:30 PM

3:30 PM - 4:00 PM

  • Interviewee: Douglas Losordo
  • Trial: ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
  • Phone number:

4:00 PM

4:00 PM - 4:30 PM

  • Interviewee: Gary Ansel
  • Trial: ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
  • Phone number:

4:30 PM

4:30 PM - 5:00 PM

  • Interviewee: Ran Kornowski
  • Trial:
  • Phone number:


Return to top

Wednesday September 23, 2009

8:30 AM

8:30 AM - 9:00 AM

  • Interviewee: William Fearon
  • Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
  • Phone number:

9:00 AM

9:00 AM - 9:30 AM

  • Interviewee: Lorenz Raber
  • Trial: SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents
  • Phone number:

9:30 AM

9:30 AM - 10:00 AM

  • Interviewee: Volker Klauss
  • Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
  • Phone number:

10:00 AM

10:00 AM - 10:30 AM

  • Interviewee: Deepak Bhatt
  • Trial: 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

  • Phone number:

10:30 AM

10:30 AM - 11:00 AM

  • Interviewee: David Cohen
  • Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI
  • Phone number:

11:00 AM

11:00 AM - 11:30 AM

  • Interviewee: Chris Cannon
  • Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
  • Phone number:

12:00 PM

12:00 PM - 12:30 PM

  • Interviewee: Robert Byrne
  • Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents
  • Phone number:


Return to top

Thursday September 24, 2009

12:45 PM

12:45 PM - 1:15 PM

  • Interviewee: Cheol Whan Lee
  • Trial: 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
  • Phone number:

1:15 PM

1:15 PM - 1:45 PM

  • Interviewee: Flavio Ribichini
  • Trial: CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
  • Phone number:

1:45 PM

1:45 PM - 2:15 PM

  • Interviewee: Josef Veselka
  • Trial: STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
  • Phone number:

2:15 PM

2:15 PM - 2:45 PM

  • Interviewee: Patrick Ohlmann
  • Trial: MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
  • Phone number:

2:45 PM

2:45 PM - 3:15 PM

  • Interviewee: Junbo Ge
  • Trial: NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
  • Phone number:

3:15 PM

3:15 PM - 3:45 PM

  • Interviewee: Giulio Guagliumi
  • Trial: OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
  • Phone number:

3:45 PM

3:45 PM - 4:15 PM

  • Interviewee: Josep Rodes-Cabau
  • Trial: The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
  • Phone number:

4:15 PM

4:15 PM - 4:45 PM

  • Interviewee: Dirk Walter
  • Trial: PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
  • Phone number:


Return to top

Friday September 25, 2009

10:30 AM

10:30 AM - 11:00 AM

  • Interviewee: Simon Redwood
  • Trial: BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
  • Phone number:

11:00 AM

11:00 AM - 11:30 AM

  • Interviewee: Arnold Seto
  • Trial: FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
  • Phone number:

12:30 PM

12:30 PM - 1:00 PM

  • Interviewee: Rolf Michels
  • Trial: DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
  • Phone number:

1:00 PM

1:00 PM - 1:30 PM

  • Interviewee: Gregg Stone
  • Trial: 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI

  • Phone number:

1:30 PM

1:30 PM - 2:00 PM

  • Interviewee: Henry Krum
  • Trial: SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
  • Phone number:


Return to top

Retrieved from "https://www.wikidoc.org/index.php?title=TCT_2009_schedule&oldid=559641"